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Background and Objective: Only a few studies have reported long-term efficacy of 
interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult-onset 
Still disease (AOSD). Herein we report on the effectiveness of anakinra (ANA), expressed 
in terms of drug retention rate (DRR), and evaluate the predictive factors of drug survival 
in a cohort of patients with sJIA and AOSD.
Patients and Methods: This is a multicenter study reviewing retrospectively the medical 
records from 61 patients with sJIA and 76 with AOSD, all treated with ANA in 25 Italian 
tertiary referral centers.
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INTRODUCTION
Systemic juvenile idiopathic arthritis (sJIA) and adult-onset 
Still disease (AOSD) represent two multifactorial nonhereditary 
autoinflammatory disorders related to pediatric and adult 
patients, respectively, characterized by a defective control of 
innate immunity, as depicted for hereditary autoinflammatory 
disorders, and by daily high spiking fevers along with systemic 
features including serositis, evanescent rash, generalized 
lymphoadenopathy, and arthritis (Caso et al., 2014; Cimaz, 
2016; Rigante, 2017; Giacomelli et al., 2018; Lyseng-Williamson, 
2018). These two conditions are accompanied by a relevant risk 
of mortality (Priori et al., 2010; Kimura et al., 2013; Minoia et al., 
2014; Kumar, 2016; Giacomelli et al., 2018), making a timely 
diagnosis as well as a prompt treatment mandatory. Treatment 
of both sJIA and AOSD has traditionally relied on nonsteroidal 
anti-inflammatory drugs, corticosteroids (CS), and conventional 
disease-modifying antirheumatic drugs (cDMARDs), with 
methotrexate being the most frequently used (Gerfaud-Valentin 
et al., 2014; Kumar, 2016). However, there is limited evidence, 
especially for sJIA, regarding other effective drugs, such as 
cyclosporine, thalidomide, and other novel agents (Kumar, 
2016; Mauro et al., 2017). The lack of standardized therapeutic 
guidelines represents an important unmet need, and management 
of both sJIA and AOSD still remains empirical. Biotechnological 
drugs have also proved to be effective in AOSD (Ruscitti et al., 
2017), and indeed many compelling pathogenetic data (Pascual 
et al., 2005; Church et al., 2008; Mellins et al., 2011; Gerfaud-
Valentin et al., 2014) consider interleukin (IL)-1 as the main 
orchestrating cytokine in sJIA and AOSD pathways, providing 
the biologic rationale of IL-1 inhibition in these two entities, 
which are now deemed autoinflammatory in nature (Hayem, 
2009; Rossi-Semerano and Koné-Paut, 2012).
Anakinra (ANA) is a recombinant human IL-1 receptor 
“antagonist,” which binds tightly to the IL-1 receptor and 
competitively prevents activation of this receptor by either IL-1α 
and IL-1β (Mistry et al., 2017). After showing its paramount 
efficacy in the cryopyrin-associated periodic syndrome, a rare 
IL-1-mediated hereditary autoinflammatory disorder (Cantarini 
et al., 2011; Rigante, 2018), ANA started to be employed also in 
AOSD and sJIA. From its first use on AOSD (Rudinskaya and 
Trock, 2003) and sJIA (Verbsky and White, 2004), a growing 
body of evidence has reported the considerable clinical efficacy 
of ANA in both entities (Quartier et al., 2011; Nordström et al., 
2012; Sfriso et al., 2016; Colafrancesco et al., 2017) with several 
studies suggesting this targeted biologic therapy as first- or early 
second-line treatment (Pascual et al., 2005; Moulis et al., 2010; 
Nigrovic et al., 2011; Hedrich et al., 2012; Vastert et al., 2014; 
Pardeo et al., 2015). Nevertheless, only a few data are available 
in regard to long-term efficacy and tolerability of ANA in sJIA 
and AOSD (Lequerré et al., 2008; Laskari et al., 2011; Giampietro 
et al., 2013; Ortiz-Sanjuán et al., 2015; Colafrancesco et al., 2017).
Herein, we report a multicenter real-life experience on 
patients with sJIA and AOSD in the long term, evaluating ANA 
Results: The cumulative retention rate of ANA at 12-, 24-, 48-, and 60-month of 
follow-up was 74.3%, 62.9%, 49.4%, and 49.4%, respectively, without any significant 
differences between sJIA and AOSD patients (p = 0.164), and between patients treated 
in monotherapy compared with the subgroup coadministered with conventional disease-
modifying antirheumatic drugs (cDMARDs) (p = 0.473). On the other hand, a significant 
difference in DRR was found between biologic-naïve patients and those previously 
treated with biotechnologic drugs (p = 0.009), which persisted even after adjustment for 
pathology (p = 0.013). In the regression analysis, patients experiencing adverse events 
(AEs) {hazards ratio (HR) = 3.029 [confidence interval (CI) 1.750–5.242], p < 0.0001} and 
those previously treated with other biologic agents [HR = 1.818 (CI 1.007–3.282), p = 
0.047] were associated with a higher HR of ANA discontinuation. The median treatment 
delay was significantly higher among patients discontinuing ANA (p < 0.0001). Significant 
corticosteroid-sparing (p = 0.033) and cDMARD-sparing effects (p < 0.0001) were also 
recorded. Less than one-third of our cohort developed AEs, and 85% were deemed mild 
in nature, with 70% of them involving the skin.
Conclusions: Our findings display an overall excellent DRR of ANA on the long run 
for both sJIA and AOSD, that may be further optimized by closely monitoring patient’s 
safety issues and employing this IL-1 inhibitor as a first-line biologic as early as possible. 
Moreover, ANA allowed a significant drug-sparing effect and showed an overall good 
safety profile.
Keywords: anakinra, interleukin 1-beta, innovative biotechnologies, drug retention rate, systemic juvenile 
idiopathic arthritis, adult onset Still disease, personalized medicine
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effectiveness in terms of drug retention rate (DRR) along with 
predictive factors associated with treatment withdrawal.
PATIENTS AND METHODS
Study Design and Participants
Medical records of 61 patients affected by sJIA and 76 patients 
affected by AOSD, all treated with ANA and enrolled from 
January 2008 until July 2016 in 25 Italian tertiary rheumatology 
referral centers, were retrospectively reviewed. Clinical and 
therapeutic data were collected in combination with general 
and demographic data, such as age, gender, age at disease onset, 
disease duration, treatment delay, the anti-IL-1 agent employed, 
dosages used, concomitant and previous treatments, and overall 
anti-IL-1 treatment duration.
sJIA was diagnosed according to the revised International 
League of Association for Rheumatology (ILAR) criteria (Petty 
et al., 2004), while AOSD diagnosis was established according to 
the Yamaguchi criteria (Yamaguchi et al., 1992). In accordance 
with the best standards of care, all patients were systematically 
followed-up every 3 months and/or in case of necessity (disease 
flare and/or safety issues). Before starting anti-IL-1 treatment 
with ANA, patients underwent a complete medical examination 
and an extensive work-up for infectious diseases, including 
search for markers of hepatitis B and C viruses, urine culture, 
QuantiFERON test, and chest X-ray to rule out active or latent 
infections. ANA dosages ranged from 1 to 4 mg/kg/day for 
pediatric patients, while 100 mg/day was the starting dose for 
adult patients.
Aims and Endpoints
Primary aim of the study was to examine the overall DRR of 
ANA in sJIA and AOSD patients. Secondary aims were to: (i) 
explore the influence of the biologic line of treatment and the 
concomitant use of cDMARDs on DRR in the whole sample 
and stratified according to the disease thereafter; (ii) find 
eventual predictive factors associated with events leading to 
drug discontinuation. The CS- and cDMARDS-sparing effects, 
impact of treatment delay on survival, and record of safety 
profile were considered ancillary aims of the study.
The primary endpoint was evaluated by the Kaplan–Meier 
survival curve at 12, 24, 48, and 60 months of follow-up. 
Secondary endpoints were as follows: (i) using limit estimators 
to compare survival curves of monotherapy versus combination 
therapy with cDMARDs and significant differences on survival 
curves, distinguishing between biologic-naïve patients and 
those already treated with other biologics; the analysis was then 
extended by stratifying limit estimators according to the disease; 
(ii) to evaluate whether demographic, clinical, and therapeutic 
variables could predict time-to-treatment discontinuation. 
Finally, ancillary aims were explored by the identification 
of potential statistically significant differences in the mean 
treatment delay, subdividing our sample in patients continuing 
and patients discontinuing treatment as well as on CS- and 
cDMARDs-sparing effect, and description of AEs.
Statistical Analysis
Data were analyzed using IBMSPSS Statistics for Windows, 
version 24 (IBM Corp., Armonk, NY, USA). Descriptive statistics 
was used to display mean and standard deviation (SD) or median 
and interquartile ranges (IQRs), as required. We analyzed data 
distribution with the Shapiro–Wilk test. Categorical variables 
were analyzed by McNemar test for repeated measures, while 
differences in means were investigated with Mann–Whitney U test. 
Time-to-event analysis was performed according to the Kaplan–
Meier method, with the event being ANA discontinuation. 
Patients discontinuing ANA due to remission were not included 
in the statistical analysis. Survival curves were compared using 
both long-rank and Breslow test as limit estimators. Event-free 
survival was assessed with a Cox proportional hazard model, 
using 95% confidence interval (CI) for hazard ratio (HR) aiming 
to evaluate any relation of demographic, clinical, and therapeutic 
data with DRR. The threshold for statistical significance was set 
to p < 0.05, and all p values were two-sided.
RESULTS
We examined medical charts of 137 patients (56 males, 81 
females) affected by sJIA (61 patients) and AOSD (76 patients), 
all receiving ANA within the study period lasting from January 
2008 to July 2016.
Demographic, clinical, and therapeutic data of sJIA and 
AOSD are detailed in Tables 1 and 2, respectively. Female-to-
male ratio was 1.03 for sJIA patients and 1.92 for the AOSD 
ones. The median ± IQR time of treatment duration was 18.00 
± 27.00 months. The mean ± SD age at disease onset for AOSD 
was 39.98 ± 15.05, while the median age ± IQR at disease onset 
for sJIA was 5.80 ± 7.10 years. Forty-two out of 137 patients 
were coadministered with cDMARDs, and 25 subjects had been 
previously treated with other biologic agents.
TABLE 1 | Demographic and therapeutic features of patients with sJIA.
Patients no. 61
Male/Female no. 30/31
Mean age ± SD (years) 12.97 ± 7.05
Age at onset (median ± IQR) 
(years)
5.80 ± 7.10
Age at diagnosis (median ± 
IQR) (years)
6.70 ± 7.30
Disease duration (median ± 
IQR) (years)
4.00 ± 5.93
Treatment delay (median ± 
IQR) (years)
2.10 ± 6.64
Previous biologics ETN (n = 9); IFX (n = 1); ADA (n = 1); TCZ (n = 
2); CAN (n = 1); RTX (n = 1); ABA (n = 1).
Previous cDMARDs MTX (n = 14); CsA (n = 13); SSZ (n = 2); LFN 
(n = 2); HCQ (n = 2)
Concomitant cDMARDs MTX (n = 8); CsA (n = 8); SSZ (n = 1); LFN (n = 
1); HCQ (n = 2)
ABA, abatacept; ADA adalimumab; CAN, canakinumab; CsA cyclosporine; 
ETN, etanercept; HCQ, hydroxychloroquine; IFX, infliximab; LFN, leflunomide; 
MTX, methotrexate; RTX, rituximab; SSZ, sulfasalazine; TCZ, tocilizumab; 
sJIA, systemic juvenile idiopathic arthritis; IQR, interquratile range; cDMARDs, 
conventional disease modifying anti-rheumatic drugs.
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The cumulative retention rate of ANA at 12, 24, 48, and 
60 months of follow-up was 74.3%, 62.9%, 49.4%, and 49.4%, 
respectively (Figure 1A), without any significant differences 
between sJIA and AOSD patients (p = 0.164) (Figure 1B). 
Conversely, statistically significant differences were observed 
between biologic-naïve patients and those previously treated 
with other biologic drugs (p = 0.009) (Figure 2A). The difference 
between the two subgroups persisted also after adjustment for 
pathology (p = 0.013). In addition, no statistically significant 
differences were detected between patients in monotherapy 
and the subgroup coadministered with cDMARDs (p = 0.473) 
(Figure 2B). Cox regression analysis identified two variables 
associated with a higher hazard of treatment withdrawal: line of 
biologic treatment and AEs. More in detail, patients previously 
treated with other biologics displayed a higher HR [HR = 
1.818 (CI 1.007–3.282), p = 0.047]. Similarly, the subgroup 
experiencing the occurrence of AEs was also associated with 
a higher hazard of treatment discontinuation [HR = 3.029 (CI 
1.750–5.242), p < 0.0001].
Moreover, the median treatment delay was significantly higher 
among patients discontinuing ANA (4.00 ± 6.83 years) compared 
to the subgroup that was able to retain it (0.66 years ± 3.24) (p 
TABLE 2 | Demographic and therapeutic data of patients with AOSD.
Patients no. 76
Male/Female no. 26/50
Mean age ± SD (years) 47.90 ± 15.13
Age at onset (mean ± SD) 
(years)
39.98 ± 15.05
Age at diagnosis 
(mean ± SD) (years)
41.96 ± 14.49
Disease duration 
(median ± IQR) (years)
6.00 ± 9.00
Treatment delay 
(median ± IQR) (years)
3.25 ± 7.47
Previous biologics ETN (n = 9); IFX (n = 6); ADA (n = 3); GOL (n = 1); 
TCZ (n = 1); RTX (n = 1)
Previous cDMARDs MTX (n = 42); CsA (n = 18); SSZ (n = 4); LFN (n = 
2); HCQ (n = 19); AZA (n = 4); CPH (n = 1); CQN 
(n = 2); COL (n = 2).
Concomitant cDMARDs MTX (n = 18); CsA (n = 4); SSZ (n = 1); LFN (n = 
2); HCQ (n = 7)
ADA, adalimumab; AZA, azathioprine; CQN, chloroquine; COL, colchicine; CPH, 
cyclophosphamide; CsA, cyclosporine; ETN, etanercept; GOL, golimumab; HCQ, 
hydroxychloroquine; IFX, infliximab; LFN, leflunomide; MTX, methotrexate; RTX, 
rituximab; SSZ, sulfasalazine; TCZ, tocilizumab AOSD, Adult onset Still disease; IQR, 
interquartile range; cDMARDs, conventional disease modifying anti-rheumatic drugs.
FIGURE 1 | Kaplan–Meier curves describing the cumulative survival of Anakinra 
related to: (A) the entire cohort of patients, (B) the log rank test comparing drug 
survival in systemic juvenile idiopathic arthritis and adult onset Still disease.
FIGURE 2 | Kaplan–Meier curves comparing cumulative drug survival of 
Anakinra between biologic-naïve patients and those pretreated with other 
biologics (A), between patients undergoing monotherapy and the subgroup 
coadministered with conventional disease modifying anti-rheumatic drugs (B).
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< 0.0001). With regard to the CS-sparing effect, a significant 
reduction in the number of patients requiring the support of CS 
was found (p = 0.033). Fifteen patients were able to interrupt 
CS therapy. A significant cDMARDs-sparing effect was also 
observed (p < 0.0001) and 35 patients were able to discontinue 
treatment with immunosuppressive drugs.
AEs occurred in 40 out of 137 patients (29.2%) (11 in 
sJIA and 29 in AOSD patients), with the most frequent being 
injection site reactions (n = 18), followed by generalized skin 
rashes (n = 10), flue-like syndrome (n = 2), thrombocytopenia 
(n =  2), transient mild respiratory problems (n = 1), and 
abnormal level of liver enzymes (n = 1). With regard to 
serious AEs, two cases of pneumonia along with lower limb 
ulcers (n  =  1), myocarditis (n  =  1), dilated cardiomyopathy 
(n = 1), and macrophage activation syndrome (MAS) (n = 1) 
were recorded. Death occurred in four patients experiencing 
serious AEs (two patients with pneumonia and the remaining 
two suffering from myocarditis and dilatative cardiomyopathy, 
respectively). Overall, AEs caused treatment discontinuation 
in 29 cases. The remaining causes for discontinuing treatment 
were as follows: clinical remission (n = 25), lack of efficacy 
(n = 8), loss of efficacy (n = 15), and pregnancy (n = 1). AEs are 
summarized in Table 3.
DISCUSSION
sJIA is the pediatric counterpart of AOSD and both disorders 
represent hard-to-handle autoinflammatory conditions 
characterized by high mortality rate due to the risk of severe 
fatal complications (Kimura et al., 2013; Minoia et al., 2014; 
Lopalco et  al., 2015; Kumar, 2016; Ruscitti et al., 2016; 
Giacomelli et al., 2018). Additionally, a high percentage 
of patients with sJIA and AOSD can be refractory to CS, 
conventional immunosuppressants, and also several biologic 
agents (Nordström et al., 2012; Ortiz-Sanjuán et al., 2015; 
Giancane et al., 2016; Janow et al., 2016). Nevertheless, in the 
current biologic era, novel targeted treatments have favorably 
resized the therapeutic armamentarium for these two entities. 
Several cytokines, such as IL-1 and IL-18, processed through the 
inflammasome machinery, and also IL-6 have been implicated 
in their pathogenesis. Particularly, since IL-1 was considered 
the master mediator of inflammatory pathway in both sJIA and 
AOSD (Pascual et al., 2005; Church et al., 2008; Mellins et al., 
2011; Gerfaud-Valentin et al., 2014), an increasing experience 
of IL-1 blockade has matured over time (Lequerré et al., 2008; 
Nigrovic et al., 2011; Quartier et al., 2011; Nordström et al., 
2012; Ortiz-Sanjuán et al., 2015; Pardeo et al., 2015; Sfriso et al., 
2016; Colafrancesco et al., 2017).
In the present study we have highlighted the real-life 
experience of 25 Italian tertiary referral centers with the 
recombinant human IL-1 receptor ANA in the treatment of sJIA 
and AOSD, focusing on long-term effectiveness as well as on 
any potential differences between the two disorders. The study 
involved 61 sJIA patients and 76 ASOD patients. In the sJIA 
subgroup males and females were equally represented, whereas 
AOSD sample was skewed toward females, who composed 
65.8% of the population. This is in accordance with previous 
studies reporting almost exactly the same percentage (Sakata et 
al., 2016; Mehta et al., 2019).
Our findings suggest an overall excellent DRR of ANA in 
both sJIA and AOSD, with an estimated probability of 50% to 
persist on treatment after 5 years from its initiation. The DRR 
of ANA does not significantly differ between patients with 
sJIA and AOSD, implying a similar effectiveness of ANA for 
both disorders. The drug survival of ANA is not affected by the 
concomitant use of cDMARDs, highlighting the effectiveness 
of this specific drug when employed in monotherapy. Other 
studies reporting long-term efficacy of ANA in sJIA and AOSD 
patients had shown similar results when comparing adjunct 
therapy versus monotherapy in terms of survival analysis as well 
as clinical and laboratory response (Laskari et al., 2011, Vitale 
et al., 2019). Data reported in this study revealed the similar 
effectiveness of ANA in sJIA and AOSD, though it remains 
controversial whether sJIA and AOSD could be considered as 
an identical disease. However, based on these successful results, 
many experts contemplate these two entities as a continuum of 
one only disorder affecting different onset ages (Hayem, 2009; 
Nirmala et al., 2015; Junge et  al., 2017; Lyseng-Williamson, 
2018; Martini et al., 2019).
On the other hand, ANA DRR differs significantly between 
biologic-naïve patients and those already treated with other 
biotechnologic agents. This observation is in accordance with 
previous studies recommending ANA administration as first-
line biologic agent instead of a rescue therapy in sJIA (Nigrovic 
et al., 2011; Hedrich et al., 2012; Vastert et al., 2014; Pardeo 
et al., 2015). In addition, this option might also be applied to 
AOSD, since the difference between biologic-naïve and biologic-
exposed patients still persisted also on a stratified analysis 
after adjustment for disorder. As also shown by the regression 
analysis, the biologic line of treatment seems to be a predictive 
factor for treatment withdrawal with a significantly lower HR 
for biologic-naïve patients.
TABLE 3 | Adverse events recorded for sJIA and AOSD.
sJIA N
Injections site reaction 7
Generalized skin rash 2
Hepatic toxicity 1
Transient and mild breath problems 1
AOSD N
Injection site reaction 11




Lower limb ulcers 1
Myocarditis 1
Dilated cardiomyopathy 1
macrophage activation syndrome 1
sJIA, systemic juvenile idiopathic arthritis; AOSD, Adult onset Still disease.
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Another crucial issue is related to the demand for a 
prompt introduction of cytokine-blocking therapies to 
modify the natural disease course by preventing or reducing 
any structural damage secondary to long-term improperly 
controlled disease. The significant higher mean treatment 
delay in patients discontinuing ANA advocates for a timely 
establishment of biologic therapy. In fact, the therapeutic 
potential of IL-1 blockade may be fully explored when ANA 
is used within the “windows of opportunity,” an interesting 
concept firstly developed in 2014 (Nigrovic, 2014). Indeed, 
early treatment with IL-1 blockade is presumably able to 
alter disease progression of both sJIA and AOSD by slowing 
its evolution and avoiding permanent damages. On the other 
hand, it is also possible that patients with long-standing disease 
receiving multiple biologic agents may simply have a more 
resistant disease. Timely targeted treatment is also important 
for minimizing inappropriately high cumulative dose of CS and 
their associated detrimental side effects. Concordant with other 
authors’ observations (Lequerré et al., 2008; Laskari et al., 2011; 
Giampietro et al., 2013), in our sample, we found a CS-sparing 
effect with a significant lower number of patients requiring 
CS administration on the last follow-up visit. Noteworthy, 
Nigrovic et al. found that the majority of patients were CS-free 
by 2 months (Nigrovic et al., 2011). Interestingly, a cDMARDs-
sparing effect was also observed. The use of IL-1 inhibition 
has even reduced side effects related to cotreatments while 
increasing patient’s compliance to monotherapy (Giampietro 
et al., 2013). This drug-sparing effect is essential in the setting 
of chronic systemic inflammatory disorders in the light of the 
reduction of side effects, which is of utmost relevance in the 
pediatric age.
As for AEs, we observed a good overall safety profile for 
ANA, as only less than one-third of the patients developed AE, 
which were mild in the vast majority of cases. More in detail, 
70% of AEs involved the skin, including injection site reactions 
in 18 cases. Four cases of death occurred in our cohort of 
patients with AOSD. However, these cases are considered to be 
more likely related to the underlying preexisting comorbidities 
and/or the poor clinical condition of patients with a refractory 
or complicated AOSD (Kim et al., 2012; Kimura et al., 2013; 
Minoia et al., 2014; Kumar, 2016; Giacomelli et al., 2018). 
Additionally, only one patient with AOSD and none of 
patients with sJIA developed MAS during the follow-up 
period. In agreement with the latter, a positive experience 
with ANA in treating pediatric patients with MAS has been 
also reported (Sönmez et al., 2018). Besides their single center 
experience showing the resolution of clinical pictures as well 
as normalization of laboratory parameters, Sönmez et  al. 
performed a systematic literature review and found optimal 
results in terms of remission and safety profile of ANA in the 
treatment of MAS. On the other hand, controversial results have 
been reported with other anti-IL-1 agents (Ilowite et al., 2014; 
Grom et al., 2016). Only one episode of MAS occurred in the 
long-term extension phase of a randomized study investigating 
efficacy and safety of rilonacept in sJIA patients (Ilowite et al., 
2014). Contrarily, Grom et al. stated that MAS occurs even in 
sJIA patients properly controlled with biologic therapy (Grom 
et al., 2016). Hence, it is not possible to draw firm conclusions 
and dedicated prospective randomized studies specifically 
investigating this dreadful complication are warranted to shed 
light on this topic.
Potential limitations of our study is its retrospective 
noncomparative design. Data such as laboratory markers and 
Pouchot’s score were not collected, and therefore we could 
not assess whether they predicted treatment withdrawal or 
not. Additionally, given the absence of standardized treatment 
guidelines, the management of the single patient relied on the 
personal experience of the local physician.
CONCLUSIONS
ANA appears a promising drug in both sJIA and AOSD, also when 
the disease has a long-standing course, displaying a satisfying 
clinical effectiveness and minimizing long-term requirement 
of CS. Moreover, ANA exhibits a similar DRR in both sJIA and 
AOSD and their survival is not affected by the concomitant 
use of cDMARDs, highlighting its efficacy as monotherapy. 
A tight monitoring of safety profile is also mandatory, since it 
can significantly affect ANA DRR. Additionally, DRR is also 
significantly influenced from the biologic line of treatment, 
suggesting to employ ANA as a first-line biologic agent. Lastly, 
our results reveal a significant impact of treatment delay in 
drug discontinuation, implying that a trend toward an earlier 
initiation might be crucial to take advantage of the “windows of 
opportunity” and improve long-term outcomes of patients with 
both sJIA and AOSD.
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